Humacyte.

PositionTRIANGLE BRIEFS: DURHAM

Humacyte. a regenerative-medicine company, raised $75 million in a stock financing. The company's total funding to date is more than $330 million.

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT